US Drug Recall Register

FDA Drug Recalls

11,815 recalls · Class II, newest first

Risk Class IClass IIClass III
Status OngoingCompletedTerminated
Year 2026202520242023
Class II · Moderate risk Terminated

2-DEOXY-D-GLUCOSE Powder

Reason Penicillin Cross Contamination: potentially contaminated with penicillin

Life Science Pharmacy Inc D-0486-2016
Class II · Moderate risk Terminated

Rifampin for Injection

Reason Failed Impurities/Degradation Specifications; out-of-specification for color, impurity, and degradation

Fresenius Kabi USA, LLC NDC 63323-351-20 D-1234-2015
Class II · Moderate risk Terminated

Tri-Mix T-50/PGE 2/LIDO 2 0.09/0.32/0.04 Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1812-2015
Class II · Moderate risk Terminated

Tri-Mix T-50/PGE 2/LIDO 2 0.03/0.18/0.09 Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1811-2015
Class II · Moderate risk Terminated

Tri-Mix T-50/PGE 1 0.14/0.08 Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1810-2015
Class II · Moderate risk Terminated

Tri-Mix T-50 8.8 mg/0.29 mg/2.9 mcg Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1809-2015
Class II · Moderate risk Terminated

Tri-Mix T-106/PGE 2 0.1/0.14 Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1808-2015
Class II · Moderate risk Terminated

Tri-Mix T-106

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1807-2015
Class II · Moderate risk Terminated

Tri-Mix T-105

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1806-2015
Class II · Moderate risk Terminated

Tri-Mix T-102/PGE 2/LIDO 2 0.06/0.3/0.2 Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1805-2015
Class II · Moderate risk Terminated

Tri-Mix T-102

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1804-2015
Class II · Moderate risk Terminated

Tri-Mix T-101

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1803-2015
Class II · Moderate risk Terminated

Tri-Mix SUPER

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1802-2015
Class II · Moderate risk Terminated

Tri-Mix ST9E

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1801-2015
Class II · Moderate risk Terminated

Tri-Mix ST9C

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1800-2015
Class II · Moderate risk Terminated

Tri-Mix ST9A

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1799-2015
Class II · Moderate risk Terminated

Tri-Mix ST9A

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1798-2015
Class II · Moderate risk Terminated

Tri-Mix ST4/PGE 2/LIDO 2 0.1/0.05/0.05 Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1797-2015
Class II · Moderate risk Terminated

Tri-Mix ST4

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1796-2015
Class II · Moderate risk Terminated

Tri-Mix ST3/PGE 2/LIDO 2 0.06/0.2/0.02 Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1795-2015
Class II · Moderate risk Terminated

Tri-Mix ST2/LIDO2/PGE2 0.2/0.1/0.04

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1794-2015
Class II · Moderate risk Terminated

Tri-Mix ST2

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1793-2015
Class II · Moderate risk Terminated

Tri-Mix ST1

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1792-2015
Class II · Moderate risk Terminated

Tri-Mix MEDIUM

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1791-2015